The author is in the Neuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and the Program in Neuroscience, Harvard Medical School, Boston, Massachusetts, USA. Lo@helix.mgh.harvard.edu
The US Food and Drug Administration has approved only one therapy for ischemic stroke, recombinant tissue plasminogen activator (tPA), which can increase blood flow to damaged brain tissue—but it can also have severe side effects and must be administered shortly after stroke. Experiments combining the drug with activated protein C (APC) may provide a solution (pages 1379−1383).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
